



2150 St-Elzéar boul. O  
Laval, (Québec) H7L 4A8  
(514) 744-6792 FAX (514) 744-6272  
[www.valeantcanada.com](http://www.valeantcanada.com)

Laval, April 14<sup>st</sup>, 2014

**Re: Syprine™ (trientine hydrochloride)**

Dear Doctor/ Pharmacist:

Syprine™ is a chelating agent indicated for patients who are intolerant to Cuprimine™ (penicillamine). Syprine™ is not marketed in Canada.

Syprine™ is available to patients through Health Canada's Special Access Program (SAP). Previously, some Canadian patients were receiving Syprine™ free of charge through a compassionate use program supported by the International Wilson's Disease Association, while some hospitals were paying for the drug for patients in need of the product.

The prior model of producing Syprine™ and making it available free of charge to most of the Canadian patient community was no longer sustainable. In order to keep the product available to Canadian patients, Valeant Canada discontinued the free of charge supply of the product effective January 1<sup>st</sup>, 2014.

From that date, Syprine™ was only available at the commercial US price, as the product is not commercially available in Canada. . In an effort to keep the product available to patients at a price that can be afforded by hospitals, other payers, and patients, Valeant Canada decided to keep the same price of Syprine™ to \$821.58 per bottle of 100 capsules (250mg) that was paid before January 1<sup>st</sup>.

Please note that the SAP is discretionary and a decision to authorize or deny a request is made on a case-by-case basis. Physicians need to demonstrate that their patients with Wilson's disease have tried all marketed alternatives and the information provided in support of the request regarding the use, safety and efficacy of Syprine is complete.

If you have any questions, please do not hesitate to contact us directly.

Sincerely,

A handwritten signature in black ink, appearing to read 'S. Beauchamp'.

Sebastien Beauchamp, BSc, MBA  
Director, Market Access & Government Affairs

A handwritten signature in black ink, appearing to read 'M. Barakat'.

Maxime Barakat, MD, PhD  
Executive Director, Medical & Regulatory Affairs